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Abstract 
The increased awareness that disorders of phosphorus metabolism occur early in the course of 
chronic kidney disease, fuels interest in early intervention strategies. A post-hoc analysis of data 
from the MDRD questions the clinical relevance of early dietary phosphate restriction, so far 
considered a mainstay in the prevention and treatment of a mineral metabolism disorders. 
Although this clinical practice may be called into question, it is premature, based on available 
evidence, to justify a cease-fire in the war on dietary phosphate.  
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Editorial commentary 
A large body of evidence links disordered phosphate metabolism with adverse renal and 
cardiovascular outcomes[1]. Controlling phosphate metabolism in patients with chronic kidney 
disease (CKD) has been a major therapeutic challenge for nephrologists for decades. As 
phosphate metabolism is disrupted early in the course of CKD, a rationale exists for treating this 
disorder before the occurrence of frank hyperphosphatemia. Treatment options mainly 
comprise use of intestinal phosphate binders and limiting dietary phosphate intake. Several 
lines of evidence suggest that these strategies are effective in hyperphosphatemic advanced 
CKD, but their role in CKD patients with normal or near normal serum phosphate levels is less 
clear. In a recent pilot trial, phosphate binder therapy appeared to promote rather than 
attenuate the progression of calcification of the coronary arteries and the abdominal aorta in 
patients with moderate CKD [2]. Randomized hard endpoint studies evaluating safety and 
efficacy of a phosphate restricted diet in CKD patients not yet on dialysis are non-existing and 
unlikely to be initiated in the near future. Thus, the nephrology community will have to rely on 
observational data for dietary guidance.  In this regard, the data of Selamet et al. presented in 
this issue of Kidney Int are highly welcomed[3]. The authors performed a post-hoc analysis of 
data from the Modification of Diet in Renal Disease (MDRD) study to investigate the 
relationship between dietary phosphate intake and hard clinical endpoints in CKD stage 3-5. 
The study was negative in the sense that no association was found between baseline dietary 
phosphate intake and incidence of ESRD and (CVD-, non-CVD or all-cause) mortality in any of 
the models tested. In addition, there was no association between dietary phosphate intake and 
serum phosphate concentration. Importantly, dietary phosphate intake was assessed by 24h 
urinary phosphate excretion (UPE). This is a major strength of the study, as several data support 
the thesis that 24h UPE in steady state is a more accurate proxy of dietary phosphorus intake 
than dietary recall. Indeed, 24h UPE lacks the limitations inherent to dietary history including 
recall bias and inaccuracy of nutrient databases with regard to phosphate content of common 
food items[4]. The negative findings by Selamat et al. [3]suggest that dietary phosphate 
restriction confers no health benefits as long as serum phosphate levels are within the normal 
range. However, before drawing this far-reaching conclusion, it might be wise to carefully 
revisit the internal and external validity of the authors’ findings, and to weigh them against 
existing literature.  
Major strengths of the MDRD study cohort include the long term follow-up and throughout 
characterization of the study population allowing for multiple adjustments in the cox-
proportional hazards models. Notwithstanding these strengths, it should be emphasized that 
sample size (n=795) for this kind of epidemiological research is relatively small. O’Donnell et al., 
for example, enrolled > 100.000 individuals in an observational study with a similar setup to 
demonstrate a significant albeit modest U-shaped association between dietary salt intake, as 
assessed by 24h urinary sodium excretion, and mortality[5]. The small sample size also limited 
the exploration of non-linear relationships between dietary phosphate intake and outcomes. In 
addition to small sample size, use of single UPE measurements and residual confounding may 
have contributed to a type I statistical error. One may argue that even when associations in the 
present study were missed due to lack of power, the (narrow) 95% confidence intervals around 
the risk estimates at least indicate that associations would be modest at best and clinically 
irrelevant. This may hold true on an individual level but not on a population level. Although risk 
estimates of similar magnitude were observed in observational studies exploring the 
relationship between dietary salt and hard outcomes[5], the clinical relevance of salt reduction 
is usually not questioned.  Given the multitude of risk factors involved these low risk estimates 
should not be surprising. Evidently, subgroups of patients can be identified benefiting more 
from dietary measures than others. Like patients with hypervolemia or hypertension who 
benefit more from dietary salt reduction, CKD patients with hyperphosphatemia probably 
benefit more from dietary phosphate restriction, as compared to patients lacking these 
conditions (as were most patients enrolled in the MDRD trial). 
The baseline 24h UPE of patients enrolling in the MDRD study was considered to best capture 
individual’s usual (lifetime) phosphate intake. This assumption is questionable. The MDRD 
Study consisted of two randomized controlled trials to determine the effects of dietary protein 
restriction and strict blood pressure control. Participants were randomly assigned to follow 
either a low-protein diet (0.58 g/kg per day) or a usual-protein diet (1.3 g/kg day)[6]. As dietary 
protein is a major source of phosphate, this intervention may be anticipated to have a profound 
impact on dietary phosphate intake as well. It is furthermore uncertain whether participants 
after completion of the 3 yr-MDRD study returned to their (usual) pre-randomization diet or 
continued the diet imposed during the study. The validity of the baseline dietary data and 24h 
UPE as a measure of the usual/cumulative phosphorus exposure may thus be questioned.  
Other concerns relate to external validity. It is important to note that participants to the parent 
MDRD study[6] were recruited between 1989 and 1993 and that both diet and drug therapy 
have evolved since then. Dietary phosphate exposure, more specifically, has increased 
tremendously, mainly as a consequence of the extensive use of phosphate additives by the 
food industry.  Phosphate additives are used in food processing for a variety of reasons, 
including to extend shelf live, improve color, enhance flavor, and retain moisture. In the 90’s, 
phosphate additives contributed approximately 500 mg/d phosphate to the American diet, 
whereas today phosphate additives may contribute as much as 1000 mg/d to the average 
American diet. Dietary phosphate originating from additives and protein differ manifestly, both 
with regard to bioavailability (100 % vs 60%) and nutritional value (none vs high). Of note, mean 
baseline 24h-urinary phosphate excretion in a recent intervention trial in healthy subjects, for 
example, was 1.91 g/day, a value close to the highest exposure observed in the MDRD study[7].  
Inhibitors of the renin-angiotensin system (RAAS) are currently more widely used in the daily 
care of renal patients than in the MDRD trial era. Differences in exposure to RAAS blockade may 
be relevant regarding patient outcomes considering the increasing body of evidence suggesting 
crosstalk between phosphate metabolism and the RAAS [8].  Thus, both amount and type of 
dietary phosphate and relevant drug therapy of patients enrolled in the MDRD study differ from 
contemporaneous CKD patients, thereby limiting the external validity. This should prompt 
confirmatory studies.   
Phosphate homeostasis is coordinated and regulated by complex cross-organ talk through 
delicate hormonal networks in which PTH and FGF23 play a crucial role[4]. Compensatory 
increases of these phosphaturic hormones explain why hyperphosphatemia only occurs when 
phosphate loading is extreme and/or kidney dysfunction is severe.  High PTH and high FGF23 
levels associate with poor cardiovascular and renal outcomes, independent of serum phosphate 
levels. More than 25 years after its conception, the trade-off hypothesis still holds true.   
How to translate this evidence to daily clinical practice? The authors rightfully point to 
limitations of dietary phosphate restriction in the care of normophosphatemic CKD patients and 
emphasize the need for further studies testing the utility of phosphate reduction strategies. 
Awaiting the results of these studies (e.g. COMBINE study[9]),  dietary phosphate restriction as 
initial therapeutic measure or as an adjunct to pharmaceutical agents (phosphate binders, 
NPT2b blockers) in CKD patients presenting with disordered phosphate metabolism remains a 
valid and defendable approach.  Whereas phosphate binder therapy may not be without harm 
in normophosphatemic CKD patients[2] it is noteworthy and reassuring that the present 
observational study did not identify safety signals in the lowest dietary phosphate intake 
quartile. When targeting dietary phosphate restriction, however, focus should clearly be on 
phosphate additives and not on protein. Such an approach does not hold a threat of protein 
energy malnutrition and already proved to be feasible and efficacious in dialysis patients. The 
least what this study should provoke is a cease-fire in the war on phosphate additives.  
 
Figure legend: 
Pathways linking dietary phosphorus to chronic kidney disease (CKD), cardiovascular disease 
(CVD) and mortality. Solid lines denote established pathways; broken lines denote pivotal 
pathways. Of note, dietary phosphorus is only one out of the many factors impacting on the 
kidneys and cardiovascular system.  
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